Exopharm Ltd
ASX:EX1

Watchlist Manager
Exopharm Ltd Logo
Exopharm Ltd
ASX:EX1
Watchlist
Price: 0.023 AUD Market Closed
Market Cap: AU$1.6m

Net Margin

-357.7%
Current
Declining
by 133.1%
vs 3-y average of -224.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-357.7%
=
Net Income
AU$-4.3m
/
Revenue
AU$1.2m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-357.7%
=
Net Income
AU$-4.3m
/
Revenue
AU$1.2m

Peer Comparison

Country Company Market Cap Net
Margin
AU
Exopharm Ltd
ASX:EX1
1.6m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

In line with most companies in Australia
Percentile
33rd
Based on 4 004 companies
33rd percentile
-357.7%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Exopharm Ltd
Glance View

Market Cap
1.6m AUD
Industry
Biotechnology

Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm is focused on developing and commercializing exosomes as therapeutic agents. The firm has three technologies that allows customization of exosomes, in which the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types. Its LEAP manufacturing technology provides access to exosomes for research and clinical uses. The firm is developing Engineered EVs (EEVs), are an emerging form of precision medicine with application in areas, such as neurology, cardiology and oncology. Its EEV projects under development are Fortrexo, Cognevo and PlexoDOX.

EX1 Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-357.7%
=
Net Income
AU$-4.3m
/
Revenue
AU$1.2m
What is Exopharm Ltd's current Net Margin?

The current Net Margin for Exopharm Ltd is -357.7%, which is below its 3-year median of -224.6%.

How has Net Margin changed over time?

Over the last 3 years, Exopharm Ltd’s Net Margin has decreased from -276.6% to -357.7%. During this period, it reached a low of -357.7% on Jan 31, 2024 and a high of -107.2% on Dec 31, 2022.

Back to Top